A Phase 1, Dose Escalation Study Of Pf-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors

Trial Profile

A Phase 1, Dose Escalation Study Of Pf-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 21 Feb 2018

At a glance

  • Drugs PF 6664178 (Primary)
  • Indications Breast cancer; Male breast cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 15 Jan 2018 Results assessing maximum tolerated dose and recommended phase 2 dose, published in the Investigational New Drugs.
    • 08 Aug 2016 Status changed from active, no longer recruiting to discontinued.
    • 10 Jun 2016 Planned End Date changed from 1 May 2016 to 1 Jul 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top